Micro-X Limited
MX1.ASXHealth Care
Design, development and manufacturing of ultra-lightweight CNT based X-Ray products for the global healthcare and counted IED imaging security markets.
Market Data
$0.041
-0.0%$29.9M
-100000.0x
$-0.018
0.00%
-0.5%
Latest Earnings
MX1 - Appendix 4D and Half Year Financial Statements
27 February 2026
Micro-X Limited (ASX: MX1) reported HY26 revenue of $10.1M, up 155% on the prior corresponding period, driven by a $3.3M Rover mobile X-ray sale to Malaysia's Ministry of Health and strong project revenues from U.S. government contracts (ARPA-H and DHS). Net loss narrowed 24% to $6.6M, though this comparison is flattered by a $3.3M R&D tax incentive that boosted the prior period but is not recognised in the current half due to uncertainty around the <$20M revenue threshold. The auditors have flagged a material uncertainty over going concern, with the company relying on a $6.2M capital raise, $12M in contracted project receipts, and future product sales to fund operations. Key points: Revenue surged 155% to $10.1M, driven by the landmark $3.3M Rover sale to Malaysia's Ministry of Health — the largest single sale in company history — and $5.7M in project revenues from ARPA-H, DHS, Billion Prima and ASA.; Net loss improved 24% to $6.6M (or 45% on an adjusted basis excluding prior period R&D tax incentive of $3.3M), reflecting meaningful revenue scaling.; Multiple strategic milestones achieved: Full Body CT design reviews completed with ARPA-H; first Head CT prototype delivered and test bench installed at Royal Melbourne Hospital in February 2026; Passenger Checkpoint Portal and two Baggage Scanners under active TSA evaluation.
Recent Announcements
MX1 - Appendix 4D and Half Year Financial Statements
Micro-X Limited (ASX: MX1) reported HY26 revenue of $10.1M, up 155% on the prior corresponding period, driven by a $3.3M Rover mobile X-ray sale to Malaysia's Ministry of Health and strong project revenues from U.S. government contracts (ARPA-H and DHS). Net loss narrowed 24% to $6.6M, though this comparison is flattered by a $3.3M R&D tax incentive that boosted the prior period but is not recognised in the current half due to uncertainty around the <$20M revenue threshold. The auditors have flagged a material uncertainty over going concern, with the company relying on a $6.2M capital raise, $12M in contracted project receipts, and future product sales to fund operations. Key points: Revenue surged 155% to $10.1M, driven by the landmark $3.3M Rover sale to Malaysia's Ministry of Health — the largest single sale in company history — and $5.7M in project revenues from ARPA-H, DHS, Billion Prima and ASA.; Net loss improved 24% to $6.6M (or 45% on an adjusted basis excluding prior period R&D tax incentive of $3.3M), reflecting meaningful revenue scaling.; Multiple strategic milestones achieved: Full Body CT design reviews completed with ARPA-H; first Head CT prototype delivered and test bench installed at Royal Melbourne Hospital in February 2026; Passenger Checkpoint Portal and two Baggage Scanners under active TSA evaluation.
MX1 - December 2025 Half Year Results Presentation
Micro-X Limited (ASX: MX1) reported record half-year revenues of A$10.1M (155% growth) for the period ended 31 December 2025, driven by strong product sales including a A$3.3M order from Malaysian Ministry of Health and increased project revenues from government partnerships (DHS, ARPA-H, Billion Prima) totaling over A$90M in funding commitments.
Get real-time alerts for MX1
Receive AI-powered earnings summaries and instant notifications when Micro-X Limited releases results.
Register Free